# Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas

> **NCT01263418** · PHASE2 · WITHDRAWN · sponsor: **UNC Lineberger Comprehensive Cancer Center**

## Conditions studied

- Lymphoma, Non-Hodgkin
- Lymphoma, Follicular
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Low-Grade
- Lymphoma, Intermediate-Grade

## Interventions

- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT01263418
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-06
- **Primary completion:** 2016-01
- **Final completion:** 2018-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients enrolled and funding has been withdrawn.
- **Last updated:** 2015-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263418, "Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01263418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*